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  SUMMARY 
 
A growing population of long-term survivors of myeloma is now accumulating 
the ‘late effects’ not only of myeloma itself, but also of several lines of 
treatment given throughout the course of the disease. It is thus important to 
recognise the cumulative burden of the disease and treatment-related toxicity 
in both the stable and active phases of myeloma, some of which is unlikely to 
be detected by routine monitoring. We summarise here the evidence for the 
key late effects in long-term survivors of myeloma, including physical and 
psychosocial consequences (in Parts 1 and 2 respectively), and recommend 
the use of late-effects screening protocols in detection and intervention. The 
early recognition of late effects and effective management strategies should 
lead to an improvement in the management of myeloma patients, although 
evidence in this area is currently limited and further research is warranted. 
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 METHODOLOGY 
These guidelines were developed using the following stages:  
• Review of key literature from 1 April 2006 to 31 March 2016 using the 
Cochrane database (search term: myeloma) and Medline: search 
terms used were [myeloma] + late effects, long term effects, frailty, 
geriatric assessment, infection, infection prophylaxis, vaccination, 
nutrition, exercise, rehabilitation, employment, endocrine, disability, late 
treatment consequences, cancer survivorship (for all papers); and 
psychological, fatigue, second primary malignancy, quality of life, 
infection (reviews). As organ-specific areas, such as renal and bone, 
have been covered in previous guidelines, searches were not re-
performed.  
• Development of key recommendations based on randomised, 
controlled trial evidence. In the absence of randomised data, 
recommendations were developed on the basis of literature review and 
a consensus of expert opinion.  
• Updating of the levels of evidence and grades of recommendation 
using the GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) nomenclature for assessing the quality of 
evidence and providing strength of recommendations. 
(http://www.gradeworkinggroup.org/index.htm). 
• Review of the manuscript was performed by the British Society for 
Haematology (BSH) Guidelines Committee and Haemato-Oncology 
Task Force, and the BSH sounding board, comprised of 50 or more 
members of the BSH who have reviewed this Guidance and 
commented on its content and applicability in the UK setting, consistent 
with the primary target audience of UK based multidisciplinary clinical 
teams treating myeloma and its complications. Involvement of patient 
perspectives was through Myeloma UK.   
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• In preparing these guidelines, the authors have considered overall 
cost-effectiveness and budget impact of recommended interventions as 
well as clinical efficacy data and the burden / impact on patients. 
Formal health economic assessments have not been carried out. 
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INTRODUCTION  
As well as aiming to prolong life, modern cancer care needs to address the 
side effects of treatment, comorbidities and the impact of the physical disease 
and its treatment on psychological and social wellbeing (Ahmedzai and 
Walsh, 2000). In many cancers, late physical and psychosocial consequences 
following completion of treatment are increasingly recognised. These ‘late 
effects’ have been defined by the US National Cancer Institute as: ‘[A] health 
problem[s] that occur[s] months or years after a disease is diagnosed or after 
treatment has ended. Late effects may be caused by cancer or cancer 
treatment. They may include physical, mental and social problems, and 
second cancers’ (National Cancer Institute). 
With the improved outcomes for a range of cancers, increasing attention is 
merited for late disease and treatment effects and their impact on patient 
experience (Denlinger et al, 2014). Late effects are increasingly relevant to 
myeloma patients, given that they can often live for over a decade post-
diagnosis, have repeated lines of complex therapies and have long-term 
disease control in the absence of cure. 
	  
Late effects in myeloma 
Life expectancy for myeloma patients has increased significantly in the last 
10-20 years (Renshaw et al, 2010). The five-year relative survival rate for 
England rose from 19.9%/21.8% (men/women) in 1991-1995 to 37.1% (both 
sexes) in 2005-2009 and 42.2% (both sexes) in 2007-2011; and the ten-year 
rate from 8.9%/9.8% (men/women) in 1991-1995 to a level for England and 
Wales for 2007 of 19.0%/14.9% and 36.6%/28.1% (men/women) in England 
in 2010-11 (Office for National Statistics, 2011; Cancer Research UK Cancer 
Survival Group, 2012). Similar levels of improvement have been shown for the 
other countries of the UK (Woods et al, 2010), and survival rates for patients 
diagnosed today may be underestimated on the basis of current data (Cancer 
Research UK). 
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Increased life expectancy is mainly due to the availability of novel 
chemotherapeutic agents, the proteasome inhibitors and immunomodulatory 
agents and the adoption of haematopoietic stem cell transplantation (HSCT) 
(Klepin and Hurd, 2006; Bird et al, 2011; Pratt et al, 2014; Cook et al, 2014)  
as well as earlier diagnosis and improved supportive care (Snowden et al, 
2011).  
The physical health of a patient with myeloma is complex, reflecting the 
effects of the disease, other comorbidities, frailty and the ageing process. 
Myeloma treatments also have side effects, which may involve permanent 
organ damage. Patients with myeloma typically undergo courses of treatment 
followed by periods of stable remission and relapse, although the increasing 
use of consolidation and maintenance now means that many may remain on 
treatment for prolonged periods of time during disease stability. The toxicity of 
multi-drug regimens may combine with the effects of the disease, other 
comorbidities and the ageing process to diminish physical, psychological and 
social functioning. Fatigue and pain (predominantly neuropathic and/or bony) 
(Boland et al, 2013; Jordan et al, 2014; Osborne et al, 2012) are the common 
symptoms for myeloma patients and the drugs used to treat pain add to the 
burden of fatigue and other side effects, further reducing quality of life  
(Snowden et al, 2011; Boland et al, 2013; Jordan et al, 2014; Osborne et al, 
2012; Sloot et al, 2015; Bilotti et al, 2011a; Bilotti et al 2011b). Infections are 
common, especially during active disease and following HSCT (Snowden et 
al, 2011; Bilotti et al, 2011a; Bilotti et al 2011b), and are a major cause of 
morbidity and mortality.  
This leads to a complex burden for the patient and his/her family, and a high 
impact on psychosocial wellbeing and health-related quality of life (HRQoL). 
Given the extended duration of life and cumulative effects, the burden is often 
greatest in those with advancing age and multiply-relapsed disease. 
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The case for screening and management of late effects in myeloma 
A key principle of the NHS-based National Cancer Survivorship Initiative 
(NCSI; England only) is improving management of the consequences of 
treatment, from diagnosis onwards (National Cancer Survivorship Initiativea). 
Likewise ‘survivorship’, defined by the US National Cancer Institute, “focuses 
on the health and life of a person with cancer post treatment until the end of 
life. It covers the physical, psychosocial, and economic issues of cancer, 
beyond the diagnosis and treatment phases” (US National Cancer Institute).  
The combined late effects of myeloma and its treatment constitute a unique 
syndrome. Survivorship in myeloma therefore requires specialised screening, 
coordinated management and multidisciplinary care. BCSH/UK Myeloma Forum 
(UKMF) guidelines for diagnosis and management (Bird et al, 2011; Pratt et al, 2014) 
and for supportive care (Snowden et al, 2011) in myeloma have been published and 
NICE have also produced guidelines for myeloma management 
(https://www.nice.org.uk/guidance/ng35). Aspects of survivorship in myeloma 
have been previously identified by North American authors as areas of 
significant need for care and screening guidelines have been developed for 
detection of late complications relating to novel therapies and HSCT (National 
Cancer Survivorship Initiativea; Bertolotti et al, 2008; Faiman et al 2008; Smith 
et al 2008; Tomblyn et al, 2009; Bilotti et al 2011a; Bilotti et al 2011b; Richards 
et al 2011; Majhail et al 2012; Majhail and Rizzo 2013). However there is no 
comprehensive, multidisciplinary guideline document for the screening, 
management and long-term care of myeloma patients.  
 
Aims 
These guidelines highlight the key late effects and broader treatment 
consequences of myeloma, and make recommendations for screening and 
management of all patients from the start of therapy, along with other 
appropriate measures to optimise quality and quantity of life. They are 
directed primarily at myeloma clinicians and their teams in secondary care, 
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but also provide a reference for primary care clinicians and other hospital-
based specialists who will inevitably be involved in ongoing patient 
management. As this is a clinical guideline, no formal economic evaluation 
has been performed and local arrangements will determine delivery of care. 
 
PART 1. LONG-TERM PHYSICAL CONSEQUENCES  
 
Infection and immunity in myeloma  
Myeloma causes profound immunodeficiency which varies during the disease 
course and for most patients lasts lifelong. The immunodeficiency involves 
numerical and functional defects of B cells, T-cell subsets, natural killer cells, 
dendritic cells (Schutt et al, 2006; Ogawara et al, 2005; Brown et al, 2001) and 
possibly neutrophil function. This is compounded by the immunomodulatory 
effects of high-dose corticosteroids and novel agents, neutropenia and host 
factors such as immobility. 
Most myeloma patients ultimately die of infection-related causes and 
immunosuppression is directly related to disease activity. Approximately 10% of 
patients die within 3 months of diagnosis and infections are often due to 
encapsulated bacteria (Augustson et al, 2005). Atypical infections (e.g. 
cytomegalovirus (CMV), Pneumocystis jirovecii, cryptococcus) are increasingly 
seen in late-stage heavily treated patients (Teh et al, 2013). Most infections are 
not fatal but may have a major effect on HRQoL. These guidelines exclude the 
peri-HSCT period since specific guidelines already exist (Majhail and Rizzo, 
2013; Rubin et al, 2014).  
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Table 1. Myeloma timeline: Periods of severe immunosuppression and 
associated common pathogens 
Period Immunological 
effects 
Common pathogens 
At diagnosis and at 
times of aggressive 
relapse 
Disease active; 
profound 
immunosuppression. 
Bacterial infections, especially 
Streptococcus pneumoniae, 
Haemophilus influenzae and 
Escherischia coli 
Immediate post-
autologous stem cell 
transplant period 
(~one month) 
Neutropenia Bacteria associated with neutropenic 
sepsis 
Recovery post 
autograft (up to ~6 
months) 
Gradual reconstitution 
of T cell-mediated 
immunity 
Pneumocystis jirovecii 
HSV, VZV, CMV, rarely invasive 
fungal infection 
Remission Immunity improved Appropriate time for elective 
vaccinations 
Re-vaccination schedule >6 months 
after autograft 
Multiple relapses, 
increasingly 
refractory disease 
Progressive 
immunosuppression 
from underlying 
disease and multiple 
therapies 
Bacteria as above, but in addition: 
progressive diminution in resistance 
to viral infections especially HSV, 
VZV, influenza, occasional atypical 
infections e.g. aspergillus, CMV, 
cryptococcus 
 
Abbreviations: HSV, herpes simplex virus; VZV, varicella zoster virus; CMV, 
cytomegalovirus 
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   Prophylactic anti-infective drugs 
Insufficient data are available to recommend prophylactic antibiotics routinely 
at any stage of myeloma (NICE, 2016), although their importance is well 
recognised in patients with other causes of immunodeficiency, such as 
neutropenia following chemotherapy.  Trials of co-trimoxazole versus 
placebo or ciprofloxacin or co-trimoxazole versus placebo in newly-
diagnosed myeloma patients have shown limited benefits of co-trimoxazole, 
but were too small to draw reliable conclusions (Oken et al, 1996; Vesole et 
al, 2012). The current 800-patient TEAMM trial (Tackling EArly Morbidity and 
Mortality in myeloma), which compares prophylactic levofloxacin with 
placebo in newly-diagnosed myeloma patients, may address these issues 
(TEAMM). Pomalidomide treatment is associated with 23-30% risk of 
infection and it has been suggested that prophylactic antibiotics could be 
given for the initial 3 months of therapy (Dimopoulos et al, 2014). 
Ciprofloxacin and enoxacin should be used with caution, as they can interact 
via cytochrome pathways, but levofloxacin, moxifloxacin, norfloxacin and 
ofoloxacin are safe. 
Myeloma patients have an increased risk of viral infections, especially 
herpes zoster and influenza (Blimark et al, 2015). Proteasome inhibitors, 
immunomodulatory drugs (IMiDs) and high-dose corticosteroids increase this 
risk, particularly for herpes zoster reactivation (Kim et al, 2008; Chanan-
Khan, 2008). Reactivation is greatly reduced by routine antiviral prophylaxis 
during bortezomib and lenalidomide treatment  (Kouroukis et al, 2014; Pour 
et al, 2009; König et al, 2014), which should be continued for at least 6 
weeks after stopping treatment (Terpos et al, 2015). Consider continuing 
aciclovir indefinitely for patients with previous shingles (400 mg once daily 
(Vickrey et al, 2009; Pour et al, 2009) or 200 mg once daily in the presence 
of renal impairment (Minarik et al, 2012)).  
Invasive fungal infection is rare in myeloma (Chanan-Khan et al, 2008; Nucci 
and Anaissie, 2009) but oropharyngeal candidiasis can occur with prolonged 
corticosteroid therapy. 
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Recommendations on the use of intravenous immunoglobulin in myeloma 
are hampered by insufficient data (NICE, 2016; Raanani et al, 2009; Chapel 
et al, 1994; Musto et al, 1992; Hargreaves, 1992) but suggest a possible 
benefit of immunoglobulin for patients in plateau phase.  
Intravenous immunoglobulin can increase levels of antibodies to common 
pathogens in myeloma patients (Raanani et al, 2009; Sklenar et al, 1993; 
Thurmann et al, 2011; Kobold et al, 2012; Morell and Barandun, 1988). The 
appropriateness of immunoglobulin replacement should be assessed in 
terms of infection history, comorbidities, hypogammaglobulinaemia and 
failure to respond to vaccination. Immunoglobulins should be administered in 
accordance with national guidance 
(https://www.gov.uk/government/publications/clinical-guidelines-for-
immunoglobulin-use-second-edition-update.  
 
Vaccination 
The response to all vaccines is typically reduced in myeloma patients. 
Response is heterogeneous and despite blunted responses, there appears 
to be clinical benefit (Cheuk et al, 2011; Esposito et al, 2010; Musto and 
Carotenuto, 1997). Ideally, functional antibody levels should be used to 
measure response and inform further vaccination, but guidance in this area 
is lacking.  
Clear recommendations on the timing of vaccination are impossible through 
lack of data, but vaccinating a myeloma patient while on treatment or with 
active disease is likely to be less effective  (Kobold et al, 2012; Hinge et al, 
2012; Schmid et al, 1981; Public Health England, 2014) than during 
remission off therapy. Deferring vaccination may not be practical, e.g. 
seasonal flu vaccination, and may still have some efficacy (Cheuk et al, 
2011; Schmid et al, 1981). 
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Myeloma patients should only receive inactivated vaccines (Table 2). Live 
attenuated vaccines (BCG, measles, measles/mumps/rubella (MMR), oral 
typhoid, herpes zoster, rubella, yellow fever) should be avoided.  
 
Table 2. Common inactivated vaccines suitable for myeloma patients 
• Diphtheria, tetanus and polio* 
• Haemophilus influenzae b (Hib) 
• Hepatitis A 
• Hepatitis B 
• Influenza† 
• Meningococcal  
• Pneumococcal (PCV13 + PPV23)‡ 
• Typhoid injection (but NOT the vaccine given by mouth) 
• Pertussis 
 
*Oral live polio vaccine (OPV) is no longer available for routine use in UK and 
should not be used. 
† Influenza vaccines in the UK are inactivated. This may not apply in other 
countries. 
‡ See text. 
It is recommended that all myeloma patients are vaccinated yearly against 
influenza. Consider vaccinating close household contacts with both the influenza 
and the varicella-zoster vaccine (Public Health England, 2015).  It is 
recommended that myeloma patients receive the conjugate pneumococcal 
vaccine (PCV13), followed by the polysaccharide PPV23 at least two months 
later. Those who have already received a single dose of PPV23 should be 
offered PCV13 at least six months after the PPV23, to reduce the risk of 
pneumococcal serotype-specific hyporesponsiveness (Public Health England, 
2013). The Haemophilus influenzae type b vaccine (Hib) should also be 
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considered (Nix et al, 2012). Following autologous or allogeneic HSCT, patients 
are advised to follow a re-vaccination schedule according to the relevant 
guidelines for patients undergoing HSCT (NICE, 2016). 
Recommendations 
Assessment  
• Offer patients education so that they can readily recognise 
infection, understand its implications and seek help (Grade 1C). 
     Management  
Prophylaxis 
• Routinely, antibiotic prophylaxis is not recommended (Grade 2B).	  
• Offer routine prolonged antiviral prophylaxis against herpes zoster 
to patients receiving proteasome-based treatments (until at least 
•  6 weeks post-treatment) and post-HSCT (Grade 1A) and consider for 
those taking both immunomodulatory drugs with high-dose 
corticosteroids (Grade 1C).  Consider lifelong prophylaxis for those 
with previous shingles (Grade 2C). 
• Consider intravenous immunoglobulin replacement based on 
infection history, hypogammaglobulinaemia, comorbidities and 
vaccination response and in accordance with national guidance 
(Grade 1C). 
Vaccination 
• Do not offer live attenuated vaccines at any stage of myeloma 
(Grade 1B). 	  
• Ideally offer vaccination during periods of minimal disease and 
when recovered from treatment (Grade 1B).  	  
• Offer seasonal inactivated influenza and a single course of 
pneumococcal vaccination (PCV13 followed by PPV23) (Grade 1C) 
• Consider Haemophilus influenzae (Hib) vaccination (Grade 2B).  
• Offer a specific schedule of re-vaccination for patients who have 
undergone autologous or allogeneic HSCT (Grade 2B).  
	  14	  
	  
• Consider vaccination against influenza and herpes zoster for 
patients’ close contacts (Grade 2C). 
 
Renal and urogenital complications  
Renal impairment occurs in up to 50% of myeloma patients and is common at 
presentation. Patients presenting with renal failure are at high risk of early death 
(Augustson et al, 2005). Causes include cast nephropathy, infection, 
dehydration, hypercalcaemia, hyperuricaemia and renal involvement with AL 
amyloidosis, and possibly with use of non-steroidal anti-inflammatory drugs (Bird 
et al, 2011). Aggressive early management of these factors and urgent treatment 
of the underlying myeloma often improves renal function. However, even with 
initial improvement, patients presenting with renal impairment have a higher 
chance of developing worsening renal impairment at relapse. The risk of 
irreversible renal failure increases markedly with time.  
Haemorrhagic cystitis may be caused by cyclophosphamide or infections, 
particularly after HSCT, but is usually short-lived and self-limiting. The immune 
defect in myeloma can make recurrent urinary tract infections problematic; these 
infections and their treatment can result in further deterioration of renal function. 
About 10% of patients need long-term renal supportive therapy, which can have 
an impact on HRQoL (Tariman and Faiman, 2011), the range of available 
therapies for treatment of the myeloma, and survival. Chronic kidney disease 
(CKD) can be exacerbated by exposure to aminoglycosides, intravenous 
contrast agents and drugs used to treat CMV reactivation. Appropriate dose 
reductions need to be followed (Pratt et al, 2014), to avoid excessive toxicity 
such as myelosuppression. Autologous SCT is still a treatment option in patients 
with renal impairment, but has to be considered in the context of other frailties 
and comorbidities and with consideration of dose reduction in melphalan (most 
commonly to 140 mg/m2) (Saunders et al, 2014). 
Patients with CKD are at a higher risk than other patients of extra-renal 
complications such as anaemia, infection and bone loss, which may best be 
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managed collaboratively with specialists in renal medicine. Anaemia can be 
treated by blood transfusion or erythropoiesis-stimulating agents (ESAs). ESAs 
are recommended for anaemia in patients with myeloma-associated renal 
impairment (Locatelli et al, 2004). 
  
Recommendations 
Assessment 
• Offer patients information on maintenance of renal health, and 
promptly investigate any deterioration in renal function not 
obviously due to myeloma relapse (Grade 1B). 
• Routinely monitor patients with CKD for serum calcium, parathyroid 
hormone and vitamin D (Grade 1B). 
• Investigate anaemia in myeloma patients and monitor long-term for 
functional iron deficiency (Grade 1C). 
 
Management 
• Refer patients with moderate/severe renal impairment (>CKD stage 
3), renal-related hyperparathyroidism or nephrotic syndrome to a 
renal specialist (Grade 1C). 
• Optimise diabetes and blood pressure control to reduce the risk of 
progression to end-stage renal disease (Grade 1B). 
• Follow recommended dose modifications for lenalidomide and 
bisphosphonates in the case of renal impairment and avoid 
nephrotoxic drugs if possible (Grade 1B).  
• Consider ESAs for myeloma-related anaemia, with iron 
supplementation as necessary (Grade 1B). 
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Bone, endocrine and metabolic disorders  
Bone loss is a well-recognised complication of myeloma, intensive chemotherapy 
and corticosteroid usage; vitamin D deficiency, inactivity, hypogonadism, renal 
failure and secondary hyperparathyroidism and radiotherapy may also 
contribute. Features include pain, diffuse and localised osteopenia and 
osteoporosis, fractures and nerve root and cord compression. Most myeloma 
patients are routinely treated from the outset with bisphosphonates. Zoledronic 
acid, the current standard of care, has been shown to reduce skeletal-related 
events, preserve bone density and prolong progression-free and overall survival 
(Morgan et al, 2013). Preservation of bone also requires calcium and vitamin D 
supplementation, hormone replacement therapy and minimisation of exposure 
and duration of corticosteroid therapy and chemotherapy (Snowden et al, 2011; 
Miceli et al, 2011; Diamond et al, 2010).  
Intensively-treated myeloma patients show a high frequency of endocrine 
abnormalities, including hypothyroidism (in 9%) and hypogonadism (65% of 
males). Adrenal function appears to be relatively resilient despite previous pulsed 
high-dose corticosteroid therapy. Menopause may be precipitated in younger 
female myeloma patients by chemotherapy and/or radiotherapy. The prevalence 
of persistent male hypogonadism following intensive treatment raises a need for 
routine screening and appropriate advice from endocrine specialists (Greenfield 
et al, 2014). 
Body composition changes may add to increased frailty, poor mobility and 
disability (Morgan et al, 2013; Miceli et al, 2011; Narici and Maffulli, 2010). 
‘Sarcopenic obesity’, reflecting loss of muscle mass with an increase in fat, 
has been reported in a high proportion of intensively treated myeloma 
patients (Greenfield et al, 2014), which contrasts with the picture in other 
advanced cancers characterised by cachexia. Proposed causes include 
endocrine, metabolic and nutritional factors and reduced physical activity  
(Saunders et al, 2014; Locatelli et al, 2004; Morley et al, 2001; Newman et al, 
2003), along with myeloma itself, also classically associated with progressive 
loss of height. Routine measurements of weight or body mass index (BMI) 
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are poor proxies for assessment of body composition, although accurate 
assessment (e.g. by dual-energy X-ray absorptiometry (DEXA) scanning) is 
less accessible. 
 
Recommendations 
Assessment 
• Offer annual screening for endocrine disorders, for 
hypothyroidism, hypogonadism in males, and younger female 
patients for menopausal symptoms particularly following 
intensive (HSCT-based) treatments (Grade 2B) 
• Assess weight, height, BMI, waist circumference, strength and 
frailty regularly, and blood pressure, HbA1c and full lipid profile 
annually, and refer to primary care for follow-up as appropriate 
(Grade 2B).  
 
Management 
 
• Reduce bone risk with weight-bearing exercise, bisphosphonates, 
calcium/vitamin D supplementation and dietary advice (Grade 1B).  
• Offer hormone replacement in both female and male patients 
where appropriate with specialist advice (Grade 2B). 
 
Neurological and eye complications 
Spinal cord or nerve root compression is the most common neurological 
complication of newly presenting or relapsing myeloma. Chemotherapy-induced 
peripheral neuropathy (CIPN) is the most common neurological complication in 
long-term survivors, and has both peripheral and central nervous system 
(processing) components (Boland et al, 2014a). Polyneuropathy may also be a 
feature of myeloma, amyloidosis and POEMS syndrome at presentation, and/or 
	  18	  
	  
related to comorbidities such as diabetes mellitus, carpal tunnel and other nerve 
compression syndromes, CKD and vitamin deficiency.  
Management of peripheral neuropathy (PN) is summarised in the BCSH 
Guidelines in Supportive Care in Myeloma (Snowden et al, 2011). Apart from 
dose or schedule adjustment, treatment for CIPN remains symptom-directed. 
Symptoms resolve or improve in most patients, but some are left with permanent 
disability. Neurotoxic drug treatments should be used with caution in patients 
with peripheral neuropathy from any cause. Additional investigations to identify 
potential causes are warranted. 
The advancing age of the myeloma population and intermittent but high-dose 
corticosteroid usage are risk factors for cataract formation, although incidence 
in the myeloma population is unknown. Total body irradiation (TBI) is rare in 
current myeloma practice, but even in transplant patients who do not receive 
TBI, the incidence of cataracts may be as high as 5–20% at 10 years (Schutt 
et al, 2006). Risks of diabetic eye disease may be increased in myeloma 
patients by high-dose corticosteroids.  
Recommendations 
Assessment 
• Screen all patients with PN with thyroid function tests, vitamin B12, 
diabetes and renal compromise (Grade 2C).  
• Offer a specialist neurology assessment in patients with Grade II-IV 
PN (Grade 2C). 
• Consider annual ophthalmic screening for cataract and other ocular 
problems. (Grade 2C). 
Management 
• Reduce or eliminate neurotoxic agents in CIPN and offer gabapentin 
or pregabalin for long-term symptom control (Grade 1B).  
• Consider referral to a pain specialist (Grade 2C). 
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Cardiovascular and respiratory complications 
Clinical and sub-clinical cardiovascular and respiratory abnormalities occur at a 
high prevalence in intensively-treated myeloma survivors. Abnormalities of 
electrocardiography, echocardiography, natriuretic peptide levels and pulmonary 
function testing are seen in around half of patients and are associated with 
reduced HRQoL (Samuelson et al, 2016; Foley et al, 2010; Kozelj et al, 2013). 
Impaired respiratory function results from recurrent or persistent upper and lower 
airway infections, thromboembolism and chemotherapy and radiation exposure, 
as well as from common causes such as smoking (Mankikian et al, 2014). 
Ventilatory function may be affected by pain and fractures due to spinal and 
chest wall bone disease, as well as opiate analgesia. 
Sodium- and fluid-retaining effects of corticosteroids and IMiDs may add to 
cardiac problems, and cardiac amyloid should always be considered, especially 
with right-sided heart failure. Anaemia may cause cardiovascular and respiratory 
symptoms, as may a high BMI, and may respond to transfusion, ESAs and 
weight loss (Pratt et al, 2014; Boland et al, 2013; Samuelson et al, 2016). 
Risk factors for cardiovascular disease (obesity, hypertension, hyperlipidaemia 
and hyperinsulinaemia) are common in myeloma patients. The metabolic 
syndrome, a complex of truncal obesity, hypertension, hyperlipidaemia, insulin 
resistance and type II diabetes mellitus, exists in as many as 50% of patients 
following HSCT (DeFilipp et al, 2016). 
Given the extended life expectancy as a result of modern treatments, routine 
screening and lifestyle modification combined with primary and secondary 
preventive strategies are more justified to reduce cardiovascular disease. Dietary 
weight management (in overweight and obese patients) and smoking cessation 
should be encouraged. Physical activity, especially after HSCT, may be 
beneficial for both physical and psychological functioning in myeloma patients 
(Coleman et al, 2003; Dimeo et al, 1997). Physical activity should ideally be 
supervised, tailored, and form part of rehabilitation programmes.  
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As well as lifestyle modification, there is also a case for cardiovascular and 
respiratory screening for risk factors, for sub-clinical disease and in patients with 
symptoms, such as breathlessness and oedema, that could be attributed to other 
causes. Natriuretic peptide testing can be used as a ‘rule out’ test to select 
patients who need priority referral for echocardiography (Cowie et al, 2010). 
Although raised plasma B-type Natriuretic peptide (BNP) or N-Terminal pro-B-
type natriuretic peptide (NT-BNP) levels do not diagnose heart failure, they have 
a high negative predictive value: and other causes for symptoms should be 
determined. A serum BNP level less than 100 pg/ml (29 pmol/litre) or an 
NTproBNP level less than 400 pg/ml (47 pmol/litre) in an untreated patient 
makes a diagnosis of heart failure unlikely. Patients with a BNP level above 100 
pg/ml or an NTproBNP level above 400 pg/ml should have echocardiography 
and specialist assessment. Further guidance is provided by NICE 
(https://www.nice.org.uk/Guidance/CG108) (NICE, 2010). 
 
Recommendations 
Assessment 
• Offer routine screening for cardiovascular risk (Grade 2C).  
• Check natriuretic peptide (BNP or NT-BNP) with annual screening or 
when clinically indicated (Grade 2C). 
• Consider ECG, echocardiography and pulmonary function testing in 
patients at risk (including abnormal natriuretic peptide levels) or 
when clinically indicated (Grade 2C). 
      
 
Management 
• Offer counselling for lifestyle modification, including diet, weight 
control, smoking cessation and appropriate physical activity (Grade 
2C). 
• Consider referral to specialist for patients with established cardiac 
and respiratory disease (Grade 2C). 
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• Consider ESAs or blood transfusion for symptomatic anaemia 
(Grade 1B). 
 
Oral and dental hygiene  
 
Maintenance of oral and dental hygiene is relevant to all myeloma patients, 
whether or not they have undergone HSCT (Pratt et al, 2014; Snowden et al, 
2011; Schutt et al, 2006). Regular dental review will not only help identify the risk 
of bisphosphonate-related osteonecrosis of the jaw (BRONJ), but should also 
cover a broader range of issues. Oral dryness is a common side effect of 
chemotherapy, radiotherapy and some supportive care drugs. Dryness and 
decreased salivation may lead to dental problems and infections. Patients may 
complain of discomfort and hypersensitivity, taste disturbances, soreness of the 
throat (including oral candidiasis), and/or problems in speaking and swallowing. 
Oral cancers may be increased in patients following HSCT and IMiD usage. 
Recommendations 
Assessment 
• Encourage annual dental review and maintenance of oral and dental 
hygiene (Grade 2C).  
• Monitor patients needing dental surgery for BRONJ (Grade 2C). 
• Investigate non-healing lesions and consider specialist referral 
(Grade 2C). 
Management 
• Recommend rinses and other treatments e.g. artificial saliva to treat 
oral dryness and other symptoms (Grade 2C). 
 
  Gastroenterological and nutritional problems  
Bowel disturbance, particularly diarrhoea, is a common and sometimes 
persistent side effect of treatment with novel agents, such as bortezomib, and 
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histone deacetylase inhibitors such as panobinostat. Diarrhoea also occurs with 
lenalidomide; it is likely due to bile acid malabsorption and responds to bile acid 
sequestrants (Pawlyn et al, 2014). Patients with persistent diarrhoea with no 
obvious infectious aetiology need referral to a gastroenterologist to exclude 
malignancy, underlying bowel disease, AL amyloidosis and bile acid 
malabsorption. Constipation is common in myeloma patients and may be the 
result of side effects of thalidomide, opioids, anticholinergics or 5-HT3 receptor 
antagonists, or hypercalcaemia. Laxative treatment is commonly used; a 
combination of a stool softener with a stimulant. 
Ongoing nausea and emesis may occur due to anti-myeloma therapy, 
analgesics, renal failure and hypercalcaemia. Anorexia is common during HSCT, 
when significant weight loss and nutritional deficiencies can occur (Murray and 
Pindoria, 2009; Iverson et al, 2009). Correctable nutritional deficiencies may be 
due to poor appetite, sub-optimal diet and insufficient exposure to sunlight. In 
common with the general population (Greenfield et al, 2014), a substantial 
proportion of patients have evidence of vitamin D insufficiency, potentially 
compounding myeloma bone disease, fatigue and other symptoms (Diamond et 
al, 2010; Greenfield et al, 2014; Maier et al, 2015). Folate deficiency and 
reduced vitamin B12 levels are relatively common although serum paraproteins 
may interfere with vitamin B12 measurement (Greenfield et al, 2014; 
Wongrakpanich et al, 2015). Iron deficiency is rare but raised serum ferritin 
levels, which appear to relatively common in patients with advanced myeloma, 
are likely to be multifactorial in origin. Diagnosis of iron overload therefore 
requires more specialised investigation (Greenfield et al, 2014).  
Abnormal liver function tests may be caused by a variety of causes, including 
drugs, infections and lifestyle factors, including alcohol consumption (Boland et 
al, 2013). 
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Recommendations 
Assessment 
• Routinely monitor weight, dietary intake and upper and lower 
gastrointestinal (GI) symptoms (Grade 2C).   
• Routinely assess liver function tests, drug and alcohol history 
(Grade 2C). 
• Consider screening annually for vitamin D, B12, folate and ferritin 
levels (Grade 2C). 
Management 
• Correct nutritional deficiencies (Grade 2C). 
• Consider referral to a dietician in patients losing weight (Grade 2C)  
• Consider referring patients with unexplained weight loss, altered 
bowel habit or abnormal liver function tests for specialist 
assessment (Grade 2C). 
 
 
Second primary malignancies  
An increase in therapy-related myelodysplastic syndrome (MDS) and acute 
myeloid leukaemia (AML) in patients with myeloma was first recognised several 
decades ago and again more recently in patients on lenalidomide maintenance 
therapy. The risk of developing MDS or AML is increased 8- to 11-fold compared 
to the general population (Mailankody et al, 2011; Roeker et al, 2013; Matarraz et 
al, 2012; Thomas et al, 2012; Barlogie et al, 2008) particularly with prolonged 
exposure to alkylating agents, most notably melphalan (Kyle et al, 1970; 
Bergsagel et al, 1979; Anon, 2000; Cuzick et al, 1987; Greene et al, 1986). 
Three large randomised trials of lenalidomide maintenance have all shown a 
small excess of second primary malignancies (SPMs) in lenalidomide-treated 
patients compared to the placebo-treated patients (IFM 2005-02 (Attal et al, 
2012), CALGB 100104 (McCarthy et al, 2012), and MM-015 (Palumbo et al, 
2012)). Other reports have supported an incidence for SPMs of up to 6.9% 
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(Srivastava et al, 2013; Palumbo et al, 2014; Dimopoulos et al, 2011). However 
Thomas et al (2012) highlighted the limitations of current studies. The risk of 
secondary AML/MDS for patients with myeloma remains low and is far 
outweighed by the current risk of toxicity and death from myeloma. The relative 
risk of myeloma patients developing solid tumours appears less than that for 
therapy-related AML/MDS, and may not be significantly above that of the general 
population. However, it is likely that SPMs will increase in patients with myeloma 
simply due to increasing survival of this ageing population. 
Recommendations 
Assessment 
• Consider AML/MDS as a potential diagnosis in patients with 
persistent or worsening cytopenias (Grade 2C).  
• Encourage vigilance for other malignancies and investigate 
suspicious symptoms promptly (Grade 2C). 
Management 
• Encourage participation in routine NHS cancer screening (Grade 
2C).	  
• Develop a system for formal recording of second primary 
malignancies and ongoing investigation for any possible links 
with treatment (Grade 2C). 
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PART 2.  FRAILTY, PSYCHOSOCIAL AND REHABILITATION 
CONSIDERATIONS 
 
Elderly and frail patients  
Myeloma has a median age at diagnosis >70 years (US National Cancer Institute 
Surveillance).	   Survival is reduced and toxicities increased in older patients 
(Bringhen et al, 2013; Palumbo et al, 2015; Wildes et al, 2014), and therefore 
assessing the impact of ageing processes on a patient is crucial in optimising 
outcomes.  As people age they become increasingly vulnerable to external 
stressors, such as infection, through a combination of frailty, disability and 
comorbidity (Table 3). The aim of assessment is threefold; to predict toxicity and 
hence modify planned treatment, provide prognostic information, and to detect 
disability (which may be supported). Older patients often choose HRQoL over 
overall survival (Fried et al, 2002; Yellen et al, 1994) and need the opportunity to 
make informed decisions about treatment. 
Table 3. Frailty, disability and co-morbidity 
Concept Definition 
Frailty A phenotype (≥3 of weakness, poor endurance, weight loss, low physical 
activity and slow gait speed (Fried et al, 2002) 
or  
as the cumulative effect of individual deficits – “the more individuals have 
wrong with them, the more likely they are to be frail” (Rockwood and 
Mitnitski, 2007).	   
Disability Difficulty or dependency in carrying out activities essential to independent 
living including tasks needed for self-care and living independently in a 
home, and desired activities important to one’s quality of life (Fried et al, 
2004). 
Comorbidity Concurrent presence of ≥2 medically diagnosed diseases in the same 
person, with the diagnosis of each contributing disease based on 
established, widely recognised criteria (Fried et al, 2004). 
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Geriatric assessment 
A Comprehensive Geriatric Assessment (CGA) is a multidimensional, 
interdisciplinary diagnostic process focusing on determining an older person’s 
medical, psychosocial and functional capabilities to develop a coordinated plan 
for treatment and long-term follow-up (Rubenstein et al, 1991). Geriatric 
assessment (GA) refers to an abbreviated assessment using a range of different 
shortened tools. No one tool has been shown to be better than another in 
oncology (Wildiers et al, 2014) and different tools emphasise different domains. 
None are as sensitive as a CGA (Hamaker et al, 2012). 
Retrospective studies show inferior outcomes in patients who experience 
toxicities and treatment discontinuations (Wildes et al, 2014). These ‘at risk’ 
patients need to be identified prospectively and treatment modified (via dose 
reduction or regimen modification). GA can identify age-related problems missed 
by a routine history and physical examination in approximately half of patients, 
(Caillet et al, 2011) and performance status underestimates the degree of 
disability (Extermann et al, 1998; Repetto et al, 2002). Although using a formal 
assessment tool versus a standard history and examination in terms of final 
outcomes and identifying the most meaningful vulnerabilities is yet to be tested 
prospectively, a systematic method can facilitate identification and correction of a 
disability. Ideally, assessment and onward referral should be done in 
collaboration with a multidisciplinary team including elderly care medicine, 
nurses and therapists as well as communicating with the GP, social care, and 
third sector services. 
A simple frailty score in myeloma includes age, comorbidities and GA.  It 
correlates well with risk of severe toxicity (Palumbo et al, 2015. The score is 
simple to use, especially in the electronic format available, but may lack 
discriminatory power for the very frail since it was based on a trial population, of 
which only 2% had a performance status of 3-4. Application of this score system 
is expected to be used increasingly in trials and may prove useful in the clinic.  
As this frailty index found age >75 to be a risk factor for increased mortality and 
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toxicity, a reasonable minimum is to assess all patients aged ≥75 and any others 
with a suggestion of frailty.  
 
Recommendations 
Assessment 
• Consider a baseline geriatric assessment in elderly and frail 
patients, particularly those aged >75 years (Grade 2C). 
• Consider using the outcome of an assessment to guide treatment 
choice and prognosis (Grade 2C). 
Management 
• Engage with elderly care teams to provide geriatric assessment, 
optimised care plans and to make joint onward referrals when 
disabilities are identified (Grade 2C). 
 
Assessment of patient concerns and information provision 
As well as physical issues, psychological problems, social factors and concern 
about treatments and maintaining independence, all have a significant impact on 
HRQoL (Frodin et al, 2010; Molassiotis et al, 2011a; Molassiotis et al, 2011b). 
After one year of follow-up, 75% of myeloma patients have deteriorating HRQoL 
scores, with 37% worrying about their future health, 34% preoccupied by their 
disease and 21% worrying about dying (Mols et al, 2012). Most HRQoL tools 
(such as the EORTC QLQ-C30 and EORTC MY-20 questionnaires of the 
European Organisation for Research and Treatment of Cancer Quality of Life) 
are used in clinical research rather than in routine clinical practice (Osborne et al, 
2012; Kvam et al, 2009). However, the MyPOS HRQoL questionnaire has been 
designed specifically for use in the clinical setting and focuses on the issues 
most important to patients (Osborne et al, 2012; Osborne et al, 2015). 
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The importance of using structured holistic needs assessments (HNA) at key 
stages of cancer from diagnosis is now recognised (Department of Health, 
Macmillan Cancer Support and NHS Improvement, 2013). The Recovery 
Package (National Cancer Survivorship Initiativeb) recommends the use of a 
HNA to identify the individual needs of the person affected by cancer at key 
points in the care pathway and if health and social needs change; ensuring that 
care is responsive to changing needs, and support services are planned and 
accessed appropriately (National Cancer Survivorship Initiative, 2012). 
The aim of an HNA is to comprehensively assess physical, emotional, mental, 
spiritual and social concerns experienced by the individual and to formulate an 
individual care or action plan (Richardson et al, 2007). Several HNA tools are 
available, for example the Sheffield Profile for Assessment and Referral for Care 
(SPARC) questionnaire (National Cancer Action Team, 2010). A recent cross-
sectional study used the SPARC tool in a group of patients with advanced, 
multiply relapsed and heavily pre-treated but stable myeloma. The patients had a 
high symptom burden, were bothered and distressed by the side effects and 
long-term effects of treatments, and were worried about the effect their disease 
was having on their family or other people (Boland et al, 2014b). 
Recommendations 
Assessment 
• Consider routine HNA at the start and end of each line of treatment 
to identify individual patient needs and concerns (Grade 2C).  
Management 
• Plan provision of support services accordingly (Grade 2C). 
• Provide information on the late effects of potential treatments and 
advise patients on strategies to reduce risk and manage treatment 
side effects (Grade 2C). 
 
	  29	  
	  
Psychological wellbeing  
Myeloma patients are concerned by disease recurrence, loss of independence, 
and death. However, overall mental functioning remains preserved, suggesting 
effective coping mechanisms (Boland et al, 2013). In a survey of 114 patients, 
anxiety (8%) and depression (24%) were reported at the time of myeloma 
diagnosis and 51% of these patients had psychosocial intervention desires. The 
most common preferences were relaxation techniques, psychological counselling 
and peer support groups (Lamers et al, 2013). Cognitive impairment, pre-
transplantation, has also been recognised leading to accentuated problems post-
transplantation: mainly deficits in learning/memory, executive function, motor 
function and psychomotor speed (Jones et al, 2013). 
Low mood, anxiety and clinical depression should be actively assessed and 
managed. A four-level model of psychological assessment and support is 
recommended by the National Institute for Health and Care Excellence (NICE) to 
guide escalation of professional intervention (National Institute for Health and 
Care Excellence, 2004). Alongside this, support groups and resources provided 
by cancer support organisations may reduce isolation and build sustainable 
support networks outside the hospital setting. 
Recommendations 
Assessment 
• Regularly assess patient mood, anxiety and cognitive status 
through HNA, patient presentation or concern, at least at the start 
and end of each line of treatment, or annually (Grade 2C).  
Management	  
 
• Escalate to psychological care or psychiatrist if clinically 
appropriate (Grade 2C). 
• Alert patients to support resources and groups outside the hospital 
setting (Grade 2C). 
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Pain and fatigue  
Myeloma patients have the highest level of symptoms and the lowest level of 
HRQoL among patients with haematological cancers (Johnsen et al, 2009). The 
influence of fatigue and pain are the strongest predictors on HRQoL in myeloma 
(Jordan et al, 2014) and these long-term consequences of treatment are known 
to be the main barriers to social and participatory functions, even in stable phase 
disease (Boland et al, 2013; Jordan et al, 2014; Gulbrandsen et al, 2004).  
A recent European multi-centre study of myeloma patients reported that 
depression and fatigue had a negative effect on HRQoL; fatigue and bone pain 
were associated with poor physical functioning whilst mental status changes 
were associated with a reduction in social functioning score (Jordan et al, 2014). 
Fatigue occurs in the majority of myeloma patients and it is usually multi-
factorial. Common treatable causes include anaemia, biochemical and endocrine 
abnormalities and use of sedating medication and other medicines such as 
corticosteroids, anti-arrhythmics, anti-hypertensives, strong analgesics and 
chemotherapy. When assessing fatigue, it is vital to ask for key components 
such as duration, and impact of rest and impact on physical and mental activity 
and sleep activity (BMJ Best Practice: Assessment of Fatigue). Exercise and 
physical activity may help; in a single arm pilot study, a tailored exercise 
programme was associated with increased muscle strength and improved fatigue 
scores (Groeneveldt et al, 2013). However, high quality trials are lacking, and 
existing evidence suggests that positive impacts on fatigue may be limited to the 
post-treatment period (Smith et al, 2015; Gan et al, 2016). Consideration should 
be given to referral to rehabilitation services. In extreme cases a trial of a central 
nervous system stimulant may be justified, but this must be delivered under 
specialist advice. 
Detailed information is given on the assessment and management of pain in 
published BCSH guidelines (Pratt et al, 2014). 
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Recommendations 
Pain 
Assessment 
• Consider routine HNA to identify individual patient needs and 
concerns (Grade 2C). 
• Take detailed history of pain using a 0-10 numerical scale, body 
chart and pain inventory and its impact (Grade 2B). 
• Assess mental health status (Grade 2B). 
• Ensure follow-up assessment as routine practice (Grade 2B). 
Management 
• Follow existing guidelines for management of pain (Grade 2C). 
Fatigue 
Assessment 
• Consider routine HNA to identify individual patient needs and 
concerns (Grade 2C). 
• Take detailed history of energy levels and fatigue, and rule out 
possible causes of fatigue, including low mood (Grade 2C). 
Management 
• Consider exercise, physical activity and rehabilitation services 
(Grade 2C). 
• Treat organic causes of fatigue, or in extreme cases, refer to generic 
chronic fatigue services. Where low mood is a factor, refer for 
counselling or psychological intervention (Grade 2C).	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Physical fitness and functionality  
Only 20% of myeloma patients meet national physical activity guidelines post-
treatment and 7% during active treatment (Jones et al, 2004; Craike et al, 2013). 
Commonly reported barriers to physical activity are pain, fear of fracture risk, 
lack of confidence and fatigue (Groeneveldt et al, 2013). Although more high 
quality randomised control trials (RCTs) are required in myeloma patients to 
determine efficacy (Gan et al, 2015; Smith et al, 2015), exercise training has 
been shown to be safe and feasible (Groeneveldt et al, 2013), with high 
attendance and adherence (Groeneveld et al, 2013; Shallwani et al, 2015) and 
higher physical activity levels have been associated with better quality of life both 
during and off active treatment (Jones et al, 2004; Groeneveld et al, 2013). 
Rehabilitation in myeloma patients after HSCT improves physical performance; 
muscle strength and aerobic capacity and immunological function; reduces 
fatigue and improves psychological outcomes (Groeneveldt et al, 2013; Persoon 
et al, 2013). 
Prehabilitation has potential to improve outcomes for this group of patients 
(Silver and Baima, 2013; Bartels et al, 2015) and should be considered prior to 
the start of treatment, in order to minimise functional decline and loss of physical 
fitness during chemotherapy. Evidence for the benefit of prehabilitation 
programmes in other cancer survivors is growing (Gillis et al, 2014). 
 
Recommendations 
Management 
• Ensure that prehabilitation and rehabilitation are an integral part of 
every line of treatment in the patient care pathway (Grade 2C) 
• Encourage regular physical activity starting from time of 
diagnosis and address patient concerns (Grade 2C) 
• Encourage continual aspiration to a generally healthy lifestyle (i.e. 
not related to myeloma treatment), including regular exercise (Grade 
2C) 
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Implications for work ability  
Work productivity loss through cancer has significant economic consequences 
for individuals, their families and society (Luengo-Fernandez et al, 2013). More 
than this, the ability to work maintains financial stability, social relationships, self-
esteem and psychological well-being (Timmons et al, 2013; Wells et al, 2013; 
Horsboel et al, 2013; Goodwin et al, 2013). Two-thirds of patients with 
haematological malignancies return to work. However, the proportion is lowest 
for myeloma and acute leukaemia patients. While myeloma mainly affects older 
people who are closer to retirement, the relatively high symptom burden and 
associated drugs may also be significant. Healthcare professionals can have a 
key influence on the likelihood of the patient’s subsequent return to work (Pryce 
et al, 2007) and should take opportunities to assess the impact of disease and 
treatment consequences have on a person’s ability to maintain their working life, 
and as a result, their identity and financial security (Wells et al, 2014). 
Recommendations 
Assessment 
• Consider routine HNA to identify individual patient needs and 
concerns (Grade 2C)  
• Signpost patients to relevant services (Grade 2C).  
• Ensure careful communication between the specialist team, GP and 
patient on suitable timing for return to work, if appropriate (Grade 
2C). 
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Conclusions: Living with myeloma	  
We are entering a watershed period in which patients are expecting to live in 
excess of 5-10 years after a diagnosis of myeloma and issues of survivorship are 
becoming increasingly important. Although care of myeloma patients is 
traditionally based around secondary care, primary care professionals need to be 
empowered to manage the consequences of the disease and its treatment.  
Analogies may be drawn from more developed examples of comprehensive care 
in other chronic but incurable diseases, such as diabetes, where both secondary 
and primary care work closely together with well- developed input from specialist 
nurses. As myeloma is a relatively rare disease state, additional training of the 
healthcare workforce may be indicated and communication between the 
secondary specialist care team and primary care is paramount. To equip patients 
to manage the late effects of myeloma, information on social and financial 
issues, return to work, travel, immunisations, relationships and sexual function, 
and psychological support is particularly important, as well as awareness of 
general health promotion strategies and routine health screening. Patients and 
families should have clear information on which health and social care team to 
contact if they have concerns.  
Recommended partners in the multidisciplinary core and supporting teams for 
assessment and treatment of myeloma late effects are summarised in Table 
4. Table 5 indicates the recommended timing and frequency for screening and 
assessment schedules. Table 6 compares these BSH guidelines with 
previously published survivorship guidelines in myeloma. Although the 
evidence base is currently limited, these guidelines and recommendations 
provide a framework for clinicians to optimise management of long-term 
complications as an important component of comprehensive care of myeloma 
as well as future areas for research and development.  
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Table 4. Recommendations for core attendance of multidisciplinary team (MDT) 
members responsible for the care of patients following completion of treatment 
 
Late effects core team 
 
Late effects MDT 
associate membership 
Social care and voluntary 
services 
 
Lead clinician 
(haematologist with 
expertise in late effects) 
General practitioner 
(individual basis) 
Social worker 
Clinical nurse specialist Geriatrician Patient support group 
Physiotherapist Liaison psychiatrist Cancer information services 
 
Psychologist Endocrinologist and 
metabolic bone physician 
Citizens Advice 
Occupational therapist Cardiologist Elderly/Cancer Charities 
 Immunologist Guidance with 
complementary therapy if 
patient expresses interest  
 Renal physician  
 Gastroenterologist  
 Respiratory physician  
 Neurologist  
 Ophthalmologist  
 Dermatologist  
 Psychosexual oncology 
counsellor 
 
 Supportive/palliative care 
consultant 
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Table 5. Recommendations for timing and frequency of assessment of late and 
long-term consequences of myeloma and its treatment: 
Long-term physical consequences 
Issue 
 
  Assessment Timing and frequency 
 
OVERALL CONDITION 
Full physical examination Annually as a minimum 
Weight maintenance 
 
Each clinic visit 
 
Height 
 
Annually without shoes -  blunt 
indication of possible vertebral 
collapse 
Blood Pressure 
 
Annually as a minimum 
Urinalysis 
 
Annually as a minimum  
Holistic needs assessment 
 
After each treatment episode and 
then annually 
 
Systems review 
 
Annually 
Drug interaction check To be made by a pharmacist at 
every treatment change 
 
INFECTION AND IMMUNITY 
 
Patient education including 
awareness of early signs of 
infection and need to seek 
medical attention without delay 
Annually, including update of unit 
self-referral policy for suspected 
infection in immunocompromised 
patients whether on or off 
chemotherapy   
Appraisal of vaccination record, 
whether transplanted or not   
 
Annually 
Influenza vaccine Annually in season 
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RENAL AND UROGENITAL 
CONDITIONS 
Monitoring of renal function 
 
At every clinic visit or at least 
every 3 months, refer for 
specialist advice if persistent 
stage 2 CKD or greater.  
 
BONE AND ENDOCRINE 
DISORDERS 
Monitoring levels of vitamin D, 
calcium 
Annually  
Screening for hypogonadism in 
males 
 
Annual serum morning 
testosterone, sex-hormone-
binding globulin and 
gonadotrophins in patients post-
HSCT or if symptomatic 
Screening for menopausal 
symptoms in females <50 years 
of age 
 
Take menopausal history and 
screen younger females for 
menopausal symptoms with 
serum oestradiol and 
gonadotrophins  
Monitoring of thyroid function 
 
Annually or if symptomatic 
 
 
NEUROLOGICAL AND 
OCULAR COMPLICATIONS 
Screening for metabolic causes 
of peripheral neuropathy: thyroid 
function, vitamin B12 levels and 
diabetes  
In all patients with peripheral 
neuropathy on presentation  
Identification of patients with 
persistent Grade II-IV peripheral 
neuropathy 
As needed - refer to neurology 
for specialised assessment. 
Screening for visual acuity, 
cataract and other ocular 
problems 
Annual eye check by opticians 
unless specific problems merit 
referral to ophthalmology 
 
SECOND PRIMARY 
MALIGNANCIES 
 
 
 
 
Monitoring for acute myeloid 
leukaemia/myelodysplastic 
syndrome in patients with 
persistent or worsening 
cytopenias 
Full blood count (FBC) each visit 
or urgently on presentation of 
suspicious signs and symptoms 
Monitoring for non-healing oral 
lesions and other malignancies 
Patient education regarding 
regular dental checks and urgent 
referral to specialist services if 
clinically indicated 
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CARDIOVASCULAR AND 
RESPIRATORY 
COMPLICATIONS 
 
Obesity/BMI/waist 
circumference/blood pressure 
At diagnosis and annually  
Assess risk factors for metabolic 
syndrome and educate patient 
and GP on increased risks. 
Non-fasting blood glucose and 
HbA1c and lipid profile. 
 
Annually, unless already on statin 
or primary care management for 
diabetes mellitus or 
hyperlipidaemia 
Patient and GP education on 
increased risks, and need for 
extra vigilance 
At annual review 
Refer to smoking cessation 
services  
As needed 
Physical activity and exercise, 
local provision such as health 
walks  
As needed 
B-type natriuretic peptide (BNP) 
or N-Terminal pro-BNP (NT-BNP) 
Annually and as clinically 
indicated 
Echocardiography/ECG  In patients at risk and repeat as 
clinically indicated 
Pulmonary function tests In patients at risk and repeat as 
clinically indicated 
ORAL AND DENTAL HYGIENE 
 
Monitoring  for bisphosphonate-
related osteonecrosis of the jaw 
(BRONJ), oral cancer, 
candidiasis 
 
 
At diagnosis and at a change in 
condition 
 
GASTROENTEROLOGICAL 
PROBLEMS AND NUTRITION 
 
 
 
 
 
 
 
 
Screening for iron overload  At diagnosis and annually in 
patients who have had blood 
transfusions 
Monitoring of vitamin D, folate, 
B12 and ferritin level 
 
At diagnosis, and annually and 
as clinically indicated 
Refer to alcohol advisory 
services via GP  
As needed 
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Table 5 continued. Recommendations for timing and frequency of assessment of 
late and long-term consequences of myeloma and its treatment: 
  Frailty, psychosocial and rehabilitation considerations 
Issue Assessment Timing and frequency 
 
ELDERLY AND FRAIL 
PARIENTS 
Consider geriatric assessment in 
elderly and frail patients, 
particularly those aged >75 years 
At baseline 
 
PSYCHOLOGICAL 
WELLBEING 
Consider routine HNA to identify 
individual patient needs and 
concerns 
At the start and end of each line 
of treatment, or annually 
Mental health and wellbeing 
(mood/anxiety/clinical 
depression) - assessment 
through HNA, patient 
presentation or concern 
At the start and end of each line 
of treatment, or annually, with 
escalation to more specialist 
support as indicated 
 
PAIN  
Consider routine HNA to identify 
individual patient needs and 
concerns 
At the start and end of each line 
of treatment, or annually and at a 
change in condition 
 
FATIGUE 
Consider routine HNA to identify 
individual patient needs and 
concerns 
At the start and end of each line 
of treatment, or annually and at a 
change in condition 
PREHABILITATION AND 
REHABILITATION 
 
 
 
 
 
Ensure that prehabilitation and 
rehabilitation are an integral part 
of every line of treatment in the 
patient care pathway  
Encourage regular physical 
activity starting from time of 
diagnosis and address patient 
concerns  
Encourage continual aspiration to 
a generally healthy lifestyle (i.e. 
not related to myeloma 
treatment), including regular 
exercise 
At diagnosis, at start and end of 
line of treatment and at a change 
in condition. 
 
 
IMPACT ON WORK ABILITY 
Consider routine HNA to identify 
individual patient needs and 
concerns 
At the start and end of each line 
of treatment, or annually 
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Table 6. Comparison of the BSH Guidelines and other international 
survivorship guidelines in myeloma 
 
  
  
BSH Guidelines for Screening and 
Management of Late and Long-term 
Consequences of Myeloma and its 
Treatments (2016) 
US Nurse Leadership Board guidelines 
(Bertolotti et al, 2008; Faiman et al 2008; Smith et al 
2008; Bilotti et al 2011a; Bilotti et al 2011b; Richards et 
al 2011) 
Multi-disciplinary writing group, including 
consumer representation, with professional 
sounding board review  
Nursing-led guidelines for multidisciplinary 
dissemination  
Emphasis on long-term disease 
complications and late effects of treatment 
along with consideration of global issues 
such as frailty and geriatric assessment  
Emphasis on key aspects of survivorship – health 
maintenance, bone, renal, sexual dysfunction, 
mobility, as well as toxicity of novel agents 
Combined medical systems and 
psychosocial model 
Topics considered to have most impact on patient 
survivorship 
One integrated guideline document, with 
systematic literature review and 
recommendations 
Several guideline documents with 
recommendations for specific areas of practice 
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ABBREVIATIONS 
 
AML  acute myeloid leukaemia 
BCSH  British Committee for Standards in Haematology 
BMI  body mass index 
BRONJ bisphosphonate-related osteonecrosis of the jaw 
BSH  British Society for Haematology 
CGA  comprehensive geriatric assessment 
CIPN  chemotherapy-induced peripheral neuropathy 
CKD  chronic kidney disease 
CMV  cytomegalovirus 
CNS  central nervous system 
DEXA  dual-energy X-ray absorptiometry 
ECG  electrocardiogram 
EORTC European Organisation for Research and Treatment of Cancer  
ESA  erythropoiesis-stimulating agent(s) 
FBC  full blood count 
GA  geriatric assessment 
GI gastrointestinal 
GRADE* Grading of Recommendations Assessment, Development and 
Evaluation (see below) 
Hib   Haemophilus influenzae type b vaccine 
HNA  holistic needs assessment 
HRQoL health-related quality of life 
HSCT  haematopoietic stem cell transplant 
HSV   Herpes simplex virus 
IMiDs  immunomodulatory drugs 
MDS  myelodysplastic syndrome 
MDT  multidisciplinary team 
MMR  measles, mumps and rubella vaccine 
NICE  National Institute for Health and Care Excellence 
NCSI  National Cancer Survivorship Initiative (England) 
NT pro-BNP B-type natriuretic peptide (BNP) test 
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ONJ  osteonecrosis of the jaw 
OPV  oral polio vaccine 
PCV13 conjugate pneumococcal vaccine 
PFT  pulmonary function test 
PN  peripheral neuropathy 
POEMS polyneuropathy, organomegaly, endocrinopathy, monoclonal 
gammopathy, and skin changes syndrome 
PPV23 pneumococcal polysaccharide vaccine 
RCT  randomised controlled trial(s) 
SCT  stem cell transplant 
SPARC Sheffield Profile for Assessment and Referral for Care  
TBI  total body irradiation 
TEAMM Tackling EArly Morbidity and Mortality in myeloma 
UKMF  UK Myeloma Forum 
VZV   Varicella zoster virus 
*GRADE: Grading of Recommendations Assessment, Development and Evaluation 
STRENGTH OF RECOMMENDATIONS: 
Strong (grade 1): Strong recommendations (grade 1) are made when there is 
confidence that the benefits do or do not outweigh harm and burden. Grade 1 
recommendations can be applied uniformly to most patients. Regard as 'recommend'. 
Weak (grade 2): Where the magnitude of benefit or not is less certain a weaker grade 2 
recommendation is made. Grade 2 recommendations require judicious application to 
individual patients. Regard as ‘suggest’. 
 
QUALITY OF EVIDENCE 
The quality of evidence is graded as high (A), moderate (B) or low (C). To put this in 
context it is useful to consider the uncertainty of knowledge and whether further 
research could change what we know or our certainty. 
(A) High.  Further research is very unlikely to change confidence in the estimate of 
effect. Current evidence derived from randomised clinical trials without important 
limitations. 
(B) Moderate. Further research may well have an important impact on confidence in 
the estimate of effect and may change the estimate. Current evidence derived from 
randomised clinical trials with important limitations (e.g. inconsistent results, 
imprecision - wide confidence intervals or methodological flaws - e.g. lack of blinding, 
large losses to follow up, failure to adhere to intention to treat analysis) or very strong 
evidence from observational studies or case series (e.g. large or very large and 
consistent estimates of the magnitude of a treatment effect or demonstration of a 
dose-response gradient). 
(C) Low.  Further research is likely to have an important impact on confidence in the 
estimate of effect and is likely to change the estimate. Current evidence from 
observational studies, case series or just opinion. 
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